Type 2 Diabetes, Healhty
Conditions
Keywords
IncretinPET
Brief summary
This study investigates how the naturally occurring gut hormones GIP and GLP-1 influence whole-body glucose uptake and organ perfusion in humans. Using a state-of-the-art total-body PET-CT scanner, the study measures dynamic uptake of the glucose analogue 18F-FDG and blood flow using H₂¹⁵O across multiple organs during controlled elevations of plasma glucose and endogenous insulin secretion. The project consists of two sub-studies. Sub-study 1 includes healthy individuals who undergo three experimental visits with infusions of GIP, GLP-1, or saline (placebo) during a hyperglycemic clamp followed by FDG PET-CT scanning. Sub-study 2 includes healthy individuals and participants with type 2 diabetes who undergo two experimental visits with saline followed by either GIP or GLP-1 during a hyperglycemic clamp, combined with repeated H₂¹⁵O PET-CT measurements of perfusion. The primary aims are to quantify insulin-mediated skeletal muscle glucose uptake (sub-study 1) and skeletal muscle perfusion (sub-study 2). Secondary aims include assessment of glucose uptake and perfusion across adipose tissue, liver, and additional organs. The results will provide novel physiological insight into postprandial glucose metabolism and serve as reference data for future whole-body PET research.
Interventions
DRUGGIP
Intravenous infusion of glucose-dependent insulinotropic polypeptide (GIP) consisting of a priming dose of 18 pmol/kg/min for 10 minutes followed by a steady-state infusion of 6 pmol/kg/min during a hyperglycemic clamp. Used to stimulate endogenous insulin secretion and mimic postprandial physiology
DRUGGLP-1
Intravenous infusion of glucagon-like peptide-1 (GLP-1) consisting of a priming dose of 4.5 pmol/kg/min for 10 minutes followed by a steady-state infusion of 1.5 pmol/kg/min during a hyperglycemic clamp. Used to stimulate endogenous insulin secretion and mimic postprandial physiology.
Intravenous infusion of isotonic saline administered as placebo. In sub-study 1, saline serves as a control condition; in sub-study 2, saline is infused for 15 minutes prior to hormone infusion.
Sponsors
Rigshospitalet, Denmark
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE
Intervention model description
Two randomized crossover studies: Sub-study 1 uses a 3-period crossover (GIP, GLP-1, placebo) in healthy individuals; Sub-study 2 uses a 2-period crossover (GIP, GLP-1) in healthy individuals and participants with type 2 diabetes.
Eligibility
Sex/Gender
ALL
Age
23 Years to 64 Years
Healthy volunteers
Yes
Inclusion criteria
Sub-study 1 (Healthy individuals): * Age 23-50 years * BMI 20.0-26.9 kg/m² * HbA1c \< 42 mmol/mol * Able to provide informed consent Sub-study 2 - Participants with Type 2 Diabetes: * Age 23-60 years * Diagnosed with type 2 diabetes for ≥3 months * HbA1c \> 53 mmol/mol * Treatment with metformin only * Able to provide informed consent Sub-study 2 - Healthy control participants: * Age 23-64 years * HbA1c \< 42 mmol/mol * Able to provide informed consent
Exclusion criteria
(applies to all participants unless otherwise specified): * Anaemia (haemoglobin below normal range) * ALT \> 2× upper normal limit or any known hepatobiliary or gastrointestinal disorder * Kidney disease (creatinine above normal range) * Previous gastric or intestinal resection (except appendectomy or cholecystectomy) or major abdominal surgery (including bariatric surgery) * For Sub-study 1: Type 1 or type 2 diabetes or HbA1c ≥ 42 mmol/mol * Use of glucose-lowering medications other than metformin (Sub-study 2 only) * Chronic obstructive pulmonary disease (Sub-study 2 only) * Regular tobacco smoking or use of nicotine-containing products * Claustrophobia * Pregnancy, breastfeeding, or intention to become pregnant during the study period * Initiation of special diets, major lifestyle changes, or weight loss \> 5% within 3 months prior to or during the study * Any medication or physical/psychological condition that may interfere with participation (per investigator judgement) * Inability to speak or read Danish
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Metabolic Rate of FDG | 75 minuts | MRFDG quantified using dynamic total-body 18F-FDG PET with 3-compartment kinetic modelling during infusion of GIP, GLP-1, or placebo. |
Secondary
| Measure | Time frame |
|---|---|
| Perfusion of skeletal muscle | 75 min |
Countries
Denmark
Contacts
CONTACTMathilde Borring Brogaard, Doctor
CONTACTPer Cramon, Doctor
Outcome results
None listed